Cited by 359TGF-β signaling in diseasesImmune Cell Function and InteractionT-cell and B-cell Immunology

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.

Open access

Arteaga, C L, Hurd, S D, Winnier, A R, Johnson, M D, Fendly, B M, Forbes, J T·1993·Journal of Clinical Investigation

Open this paper in CoChat — free account Open PDF

Abstract

TGF-beta effects on angiogenesis, stroma formation, and immune function suggest its possible involvement in tumor progression. This hypothesis was tested using the 2G7 IgG2b, which neutralizes TGF-beta 1, -beta 2, and -beta 3, and the MDA-231 human breast cancer cell line. Inoculation of these cells in athymic mice decreases mouse spleen natural killer (NK) cell activity. Intraperitoneal injections of 2G7 starting 1 d after intraperitoneal inoculation of tumor cells suppressed intraabdominal tumor and lung metastases, whereas the nonneutralizing anti-TGF-beta 12H5 IgG2a had no effect. 2G7 transiently inhibited growth of established MDA-231 subcutaneous tumors. Histologically, both 2G7-treated and control tumors were identical. Intraperitoneal administration of 2G7 resulted in a marked increase in mouse spleen NK cell activity. 2G7 did not inhibit MDA-231 primary tumor or metastases formation, nor did it stimulate NK cell-mediated cytotoxicity in beige NK-deficient nude mice. Finally, serum-free conditioned medium from MDA-231 cells inhibited the NK cell activity of human blood lymphocytes. This inhibition was blocked by the neutralizing anti-TGF-beta 2G7 antibody but not by a nonspecific IgG2. These data support a possible role for tumor cell TGF-beta in the progression of mammary carcinomas by suppressing host immune surveillance.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci116871

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro.
Roberts, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Roche, N. S., Wakefield, L. M., Heine, U., Liotta, L. A., Falanga, V., & Kehrl, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4167 · Cited by 2,867
Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth.
Kehrl, J. H., Wakefield, L. M., Roberts, A. B., Jakowlew, S. B., Álvarez‐Mon, M., Derynck, R., Sporn, M. B., & Fauci, A. S. (1986) · The Journal of Experimental Medicine · doi:10.1084/jem.163.5.1037 · Cited by 1,581
Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells
Knabbe, C., Lippman, M. E., Wakefield, L. M., Flanders, K. C., Kasid, A., Derynck, R., & Dickson, R. B. (1987) · Cell · doi:10.1016/0092-8674(87)90193-0 · Cited by 974
New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues.
Roberts, A. B., Anzano, M. A., Lamb, L. C., Smith, J. M., & Sporn, M. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5339 · Cited by 919
The Transforming Growth Factor-βs
Roberts, A. B., & Sporn, M. B. (1991) · Springer eBooks · doi:10.1007/978-1-4612-3210-0_8 · Cited by 869
Deactivation of macrophages by transforming growth factor-β
Tsunawaki, S., Sporn, M. B., Ding, A. H., & Nathan, C. (1988) · Nature · doi:10.1038/334260a0 · Cited by 862
Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta.
Postlethwaite, A. E., Keski-Oja, J., Moses, H. L., & Kang, A. H. (1987) · The Journal of experimental medicine · doi:10.1084/jem.165.1.251 · Cited by 777
Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.
Kehrl, J. H., Roberts, A. B., Wakefield, L. M., Jakowlew, S. B., Sporn, M. B., & Fauci, A. S. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.137.12.3855 · Cited by 759
Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness.
Rook, A. H., Kehrl, J. H., Wakefield, L. M., Roberts, A. B., Sporn, M. B., Burlington, D. B., Lane, H. C., & Fauci, A. S. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.10.3916 · Cited by 570
Transforming growth factor production by chemically transformed cells.
Moses, H. L., Branum, E. L., Proper, J. A., & Robinson, R. A. (1981) · PubMed · Cited by 497

Show all 40 references

Sorted by citations

TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1208 · Cited by 1,626
TGFβ: the molecular Jekyll and Hyde of cancer
Bierie, B., & Moses, H. L. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1926 · Cited by 1,291
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T. T., Chu, X., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,360
Cyclosporine induces cancer progression by a cell-autonomous mechanism
Hojo, M., Morimoto, T., Maluccio, M. A., Asano, T., Morimoto, K., Lagman, M., Shimbo, T., & Suthanthiran, M. (1999) · Nature · doi:10.1038/17401 · Cited by 1,148
Role of tissue stroma in cancer cell invasion
De Wever, O., & Mareel, M. (2003) · The Journal of Pathology · doi:10.1002/path.1398 · Cited by 1,042
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Roles of TGFβ in metastasis
Padua, D. M., & Massagué, J. (2008) · Cell Research · doi:10.1038/cr.2008.316 · Cited by 828
Genetic control of the circulating concentration of transforming growth factor type beta1
Grainger, D. J. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.1.93 · Cited by 754
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
Mamessier, É., Sylvain, A., Thibult, M., Houvenaeghel, G. F., Jacquemier, J. D., Castellano, R., Gonçalvès, A., André, P., Romagné, F., Thibault, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45816 · Cited by 722
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
Gao, Y., Souza-Fonseca-Guimarães, F., Bald, T., Ng, S. S., Young, A., Ngiow, S. F., Rautela, J., Straube, J., Waddell, N., Blake, S. J., et al. (2017) · Nature Immunology · doi:10.1038/ni.3800 · Cited by 681
TGFβ1 Inhibits the Formation of Benign Skin Tumors, but Enhances Progression to Invasive Spindle Carcinomas in Transgenic Mice
Cui, W., Fowlis, D. J., Bryson, S., Duffie, E., Ireland, H., Balmain, A., & Akhurst, R. J. (1996) · Cell · doi:10.1016/s0092-8674(00)80127-0 · Cited by 628
Apoptosis in podocytes induced by TGF-β and Smad7
Schiffer, M., Bitzer, M., Roberts, I. S. D., Kopp, J. B., ten Dijke, P., Mundel, P. H., & Böttinger, E. P. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200112367 · Cited by 597
Heterotypic Signaling between Epithelial Tumor Cells and Fibroblasts in Carcinoma Formation
Elenbaas, B., & Weinberg, R. A. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5133 · Cited by 572
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
Lahn, M. M. F., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 571
Development of TGF-β signalling inhibitors for cancer therapy
Yingling, J. M., Blanchard, K. L., & Sawyer, J. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1580 · Cited by 557
Elevated TGF-β1 Secretion and Down-Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients1
Lee, J.-C., Lee, K.-M., Kim, D.-W., & Heo, D. (2004) · Journal of Immunology · doi:10.4049/jimmunol.172.12.7335 · Cited by 488
Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte–mediated Tumor Immunosurveillance
Terabe, M., Matsui, S., Park, J.-M., Mamura, M., Noben-Trauth, N., Donaldson, D. D., Chen, W., Wahl, S. M., Ledbetter, S. R., Pratt, B. M., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022227 · Cited by 549
Roles for Growth Factors in Cancer Progression
Witsch, E., Sela, M., & Yarden, Y. (2010) · Physiology · doi:10.1152/physiol.00045.2009 · Cited by 568
Transforming growth factor-β in cancer and metastasis
Jakowlew, S. B. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9006-2 · Cited by 529
TGF-β Family Signaling in Tumor Suppression and Cancer ProgressionPreprint
Seoane, J., & Gomis, R. R. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022277 · Cited by 528
Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network
Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497
Self-citation
Inhibition of Transforming Growth Factor-β Signaling Accelerates Atherosclerosis and Induces an Unstable Plaque Phenotype in Mice
Mallat, Z., Gojová, A., Marchiol, C., Esposito, B., Kamaté, C., Merval, R., FRADELIZI, D., & Tedgui, A. (2001) · Circulation Research · doi:10.1161/hh2201.099415 · Cited by 501
Phase I study of GC1008 (fresolimumab): a human anti‐transforming growth factor‐beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma
Morris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090353 · Cited by 487
Novel therapies emerging in oncology to target the TGF‐β pathway
Kim, B.-G., Malek, E., Choi, S. H., Ignatz-Hoover, J. J., & Driscoll, J. J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01053-x · Cited by 453
The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells.
Rønnov‐Jessen, L., PETERSEN, O. W., Koteliansky, V., & Bissell, M. J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117736 · Cited by 443
Pathobiology of transforming growth factor β in cancer, fibrosis and immunologic disease, and therapeutic considerations
Prud’homme, G. J. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700669 · Cited by 424
Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects
Yang, Y.-A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215333 · Cited by 404
Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects
Yang, Y.-A., Dukhanina, O. I., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J. D., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15333 · Cited by 411
The dynamic roles of TGF‐β in cancer
Meulmeester, E., & ten Dijke, P. (2010) · The Journal of Pathology · doi:10.1002/path.2785 · Cited by 399
Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma
Enk, A., Jonuleit, H., Saloga, J., & Knop, J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971104)73:3 · Cited by 390
Overcoming TGFβ-mediated immune evasion in cancer
Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00413-6 · Cited by 377
A potential role of macrophage activation in the treatment of cancer
Klimp, A. H., de Vries, E. G. E., Scherphof, G. L., & Daemen, T. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00203-7 · Cited by 368
The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis
Neel, J.-C., Humbert, L., & Lebrun, J. J. (2012) · ISRN Molecular Biology · doi:10.5402/2012/381428 · Cited by 367
Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression
Biswas, S., Guix, M., Rinehart, C., Dugger, T. C., Chytil, A. M., Moses, H. L., Freeman, M. L., & Arteaga, C. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30740 · Cited by 346
Self-citation
Transforming growth factor beta (TGF-β) and inflammation in cancer
Bierie, B., & Moses, H. L. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.008 · Cited by 341
Metabolic reprogramming of cancer-associated fibroblasts by TGF-β drives tumor growth: Connecting TGF-β signaling with “Warburg-like” cancer metabolism and L-lactate production
Guido, C., Whitaker‐Menezes, D., Capparelli, C., Balliet, R. M., Zhao, L., Pestell, R. G., Howell, A., Aquila, S., Andò, S., Martinez‐Outschoorn, U., et al. (2012) · Cell Cycle · doi:10.4161/cc.21384 · Cited by 333
Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells
Sun, L., Wu, G., Willson, J. K. V., Zborowska, E., Yang, J., Rajkarunanayake, I., Wang, J., Gentry, L. E., Wang, X. F., & Brattain, M. G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47215-8 · Cited by 319
Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma.
McCormick, L. L., Zhang, Y., Tootell, E., & Gilliam, A. C. (1999) · PubMed · Cited by 294
Mammary tumor suppression by transforming growth factor beta 1 transgene expression.
Pierce, D. F., Gorska, A. E., Chytil, A. M., Meise, K. S., Page, D. L., Coffey, R. J., & Moses, H. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4254 · Cited by 291
Transforming growth factor-β: a therapeutic target for cancer
Haque, S., & Morris, J. C. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1327107 · Cited by 276
Anti-TGF-β Treatment Prevents Skin and Lung Fibrosis in Murine Sclerodermatous Graft-Versus-Host Disease: A Model for Human Scleroderma
McCormick, L. L., Zhang, Y., Tootell, E., & Gilliam, A. C. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5693 · Cited by 264
Cytokines and Immune Response in the Tumor Microenvironment
D, S. M. M., Wang, E., & Marincola, F. M. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200109000-00002 · Cited by 261
Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells.
Kawano, T., Nakayama, T., Kamada, N., Kaneko, Y., Harada, M., Ogura, N., Akutsu, Y., Motohashi, S., Iizasa, T., Endo, H., et al. (1999) · PubMed · Cited by 259
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
Formenti, S. C., Lee, P. P., Adams, S., Goldberg, J. D., Li, X., Xie, M. W., Ratikan, J. A., Felix, C., Hwang, L. H., Faull, K. F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3322 · Cited by 260
Diabetic nephropathy and transforming growth factor-β: transforming our view of glomerulosclerosis and fibrosis build-up
Chen, S., Jim, B., & Ziyadeh, F. N. (2003) · Seminars in Nephrology · doi:10.1053/s0270-9295(03)00132-3 · Cited by 255
Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma
Tanaka, S., Mori, M., Sakamoto, Y., Makuuchi, M., Sugimachi, K., & Wands, J. R. (1999) · Journal of Clinical Investigation · doi:10.1172/jci4891 · Cited by 255
The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine
Eyden, B. P. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00213.x · Cited by 261
Src Phosphorylates Tyr284 in TGF-β Type II Receptor and Regulates TGF-β Stimulation of p38 MAPK during Breast Cancer Cell Proliferation and Invasion
Galliher, A. J., & Schiemann, W. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3851 · Cited by 249
Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
Yoneda, T., Sasaki, A., Dunstan, C. R., Williams, P. J., Bauss, F., DeClerck, Y. A., & Mundy, G. R. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119435 · Cited by 247
Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines.
Kobie, J. J., Wu, R. S., Kurt, R. A., Lou, S., Adelman, M. K., Whitesell, L. J., Ramanathapuram, L. V., Arteaga, C. L., & Akporiaye, E. T. (2003) · PubMed · Cited by 247
Self-citation
Use of vitamins, minerals, and nutritional supplements by participants in a chemoprevention trial
Sandler, R. S., Halabi, S., Kaplan, E. B., Baron, J. A., Paskett, E., & Petrelli, N. J. (2001) · Cancer · doi:10.1002/1097-0142(20010301)91:5 · Cited by 47
Targeting TGF-β Signaling for Therapeutic GainPreprint
Akhurst, R. J. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022301 · Cited by 255
Role of TGF-? in immune-evasion of cancer
Beck, C., Schreiber, H. W., & Rowley, D. A. (2001) · Microscopy Research and Technique · doi:10.1002/1097-0029(20010215)52:4 · Cited by 105
Targeting the TGFβ signaling network in human neoplasia
Dumont, N., & Arteaga, C. L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00135-1 · Cited by 243
Self-citation
Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells
Urashima, M., Ogata, A., Chauhan, D., Hatziyanni, M., Vídriales, M., Dedera, D., Schlossman, R., & Anderson, K. C. (1996) · Blood · doi:10.1182/blood.v87.5.1928.1928 · Cited by 237
An Anti–Transforming Growth Factor β Antibody Suppresses Metastasis via Cooperative Effects on Multiple Cell Compartments
Nam, J., Terabe, M., Mamura, M., Kang, M., Chae, H., Stuelten, C. H., Kohn, E. A., Tang, B., Sabzevari, H., Anver, M. R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0215 · Cited by 235
The Fas counterattack: Cancer as a site of immune privilege
O’Connell, J., Bennett, M. W., O’Sullivan, G. C., Collins, J. K., & Shanahan, F. (1999) · Immunology Today · doi:10.1016/s0167-5699(98)01382-6 · Cited by 232
Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles
Nakagawa, H., Liyanarachchi, S., Davuluri, R. V., Auer, H., Martin, E. W., de la Chapelle, A., & Frankel, W. L. (2004) · Oncogene · doi:10.1038/sj.onc.1208013 · Cited by 232
The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-?, T-cell apoptosis, and the immune privilege of the brain
Weller, M., & FONTANA, A. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00010-0 · Cited by 229
Tumor-Associated Transforming Growth Factor-β and Interleukin-10 Contribute to a Systemic Th2 Immune Phenotype in Pancreatic Carcinoma Patients
Bellone, G., Turletti, A., Artusio, E., Mareschi, K., Carbone, A., Tibaudi, D., Robecchi, A., Emanuelli, G., & Rodeck, U. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65149-8 · Cited by 227
Role of platelets in cancer and cancer-associated thrombosis: Experimental and clinical evidences
Mezouar, S., Frère, C., Darbousset, R., Mège, D., Crescence, L., Dignat‐George, F., Panicot‐Dubois, L., & Dubois, C. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.01.006 · Cited by 218
TGF- β signaling in cancer – a double-edged sword
Akhurst, R. J., & Derynck, R. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02130-4 · Cited by 756
Crosstalk between TGF-β signaling and the microRNA machinery
Butz, H., Rácz, K., Hunyady, L., & Patócs, A. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.04.003 · Cited by 216
Targeting TGF-β signaling in cancer
Katz, L. H., Li, Y., Chen, J.-S., Muñoz, N. M., Majumdar, A., Chen, J., & Mishra, L. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.782287 · Cited by 212
Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression
Wendt, M. K., Tian, M., & Schiemann, W. P. (2011) · Cell and Tissue Research · doi:10.1007/s00441-011-1199-1 · Cited by 215
On-Target Anti-TGF-β Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges?
Teixeira, A. F., ten Dijke, P., & Zhu, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00605 · Cited by 216
Transforming Growth Factor-β in the Gastrointestinal and Hepatic Tumor Microenvironment
Achyut, B. R., & Yang, H. H. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.048 · Cited by 203
Lack of Primary Cilia Primes Shear-Induced Endothelial-to-Mesenchymal Transition
Egorova, A. D., Khedoe, P. P. S. J., Goumans, M.-J. T. H., Yoder, B. K., Nauli, S. M., ten Dijke, P., Poelmann, R. E., & Hierck, B. P. (2011) · Circulation Research · doi:10.1161/circresaha.110.231860 · Cited by 195
E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
Mbalaviele, G., Dunstan, C. R., Sasaki, A., Williams, P. J., Mundy, G. R., & Yoneda, T. (1996) · PubMed · Cited by 194
Recent progress in TGF-β inhibitors for cancer therapy
Huang, Z., Chung, C., Hu, T., Chen, J., Liu, P., & Chen, C. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111046 · Cited by 201
Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer
Silberstein, G. B., Horn, K. V., Strickland, P. A., Roberts, C. T., & Daniel, C. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8132 · Cited by 193
Basics of TGF-ß and Pancreatic Cancer
Truty, M. J., & Urrutia, R. A. (2007) · Pancreatology · doi:10.1159/000108959 · Cited by 192
Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion.
Portella, G., Cumming, S. A., Liddell, J., Cui, W., Ireland, H., Akhurst, R. J., & Balmain, A. (1998) · PubMed · Cited by 185
Regulation of Mouse NK Cell Development and Function by Cytokines
Marçais, A., Viel, S., Grau, M., Henry, T., Marvel, J., & Walzer, T. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00450 · Cited by 194
Malignant Cells, Directors of the Malignant Process: Role of Transforming Growth Factor-beta
Teicher, B. A. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1013177011767 · Cited by 177
Extracellular Signal-regulated Kinase and the Small GTP-binding Protein, Rac, Contribute to the Effects of Transforming Growth Factor-β1 on Gene Expression
Mucsi, I., Skorecki, K. L., & Goldberg, H. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.28.16567 · Cited by 176
Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer.
Yi, B., Williams, P. J., Niewolna, M., Wang, Y., & Yoneda, T. (2002) · PubMed · Cited by 172
Targeting the Transforming Growth Factor-β pathway inhibits human basal-like breast cancer metastasis
Ganapathy, V., Ge, R., Grazioli, A., Xie, W. Q., Banach-Petrosky, W. A., Kang, Y., Lonning, S. M., McPherson, J., Yingling, J. M., Biswas, S., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-122 · Cited by 171
Dual Role of Transforming Growth Factor β in Mammary Tumorigenesis and Metastatic Progression
Muraoka-Cook, R. S., Dumont, N., & Arteaga, C. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.937s.11.2 · Cited by 169
Self-citation
TGF-β as a therapeutic target in high grade gliomas – Promises and challenges
Joseph, J. V., Balasubramaniyan, V., Walenkamp, A., & Kruyt, F. A. E. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.005 · Cited by 165
Autocrine Transforming Growth Factor-β Signaling Mediates Smad-independent Motility in Human Cancer Cells
Dumont, N., Bakin, A. V., & Arteaga, C. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m204623200 · Cited by 159
Self-citation
Transforming Growth Factor-β and the Immune Response to Malignant Disease
Teicher, B. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1654 · Cited by 161
Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-β
Dumont, N., & Arteaga, C. L. (2000) · Breast Cancer Research · doi:10.1186/bcr44 · Cited by 158
Self-citation
TGF-β: A Critical Modulator of Immune Cell Function
Letterio, J. J., & Roberts, A. B. (1997) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1997.4409 · Cited by 155
Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-β Type I Receptor Kinase In vivo
Ge, R., Rajeev, V., Ray, P., Lattime, E. C., Rittling, S. R., Medicherla, S., Protter, A., Murphy, A., Chakravarty, J., Dugar, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0162 · Cited by 155
Transforming growth factor-β in breast cancer: A working hypothesis
Reiß, M., & Barcellos‐Hoff, M. H. (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005865812918 · Cited by 154
Transforming growth factor‐β in cutaneous melanoma
Javelaud, D., Alexaki, V. I., & Mauviel, A. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00450.x · Cited by 150
Characterization of intracellular calcium mobilization by bombesin-related neuropeptides in PC-3 human prostate cancer cells
Han, K., Viallet, J., Chevalier, S., Zheng, W., Bazinet, M., & Aprikian, A. G. (1997) · The Prostate · doi:10.1002/(sici)1097-0045(19970401)31:1 · Cited by 19
TGF-beta signalling in colon carcinogenesis
Lampropoulos, P., Zizi-Sermpetzoglou, A., Rizos, S., Kostakis, A. I., Nikiteas, N. I., & Papavassiliou, A. G. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.041 · Cited by 151
Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis
Kölch, W., Martiny‐Baron, G., Kieser, A., & Marm�, D. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00666036 · Cited by 142
Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft.
Bandyopadhyay, A. M., López‐Casillas, F., Malik, S. N., Montiel-Hernández, J. L., Mendoza, V., Yang, J., & Sun, L. (2002) · PubMed · Cited by 140
Transforming growth factor‐beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer
Schlingensiepen, K., Jaschinski, F., Lang, S. A., Moser, C., Geissler, E. K., Schlitt, H. J., Kielmanowicz, M., & Schneider, A. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01917.x · Cited by 139
Elevated plasma levels of transforming growth factor (TGF)-β1 and TGF-β2 in patients with disseminated malignant melanoma
Krasagakis, K., Thölke, D., Farthmann, B., Eberle, J., Mansmann, U., & Orfanos, C. E. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.245 · Cited by 138
The role of Fas ligand and transforming growth factor β in tumor progression
Kim, R., Emi, M., Tanabe, K., Uchida, Y., & Toge, T. (2004) · Cancer · doi:10.1002/cncr.20270 · Cited by 140
Suppression of natural killer cell-mediated bone marrow cell rejection by CD4 + CD25 + regulatory T cells
Barão, I., Hanash, A. M., Hallett, W. H. D., Welniak, L. A., Sun, K., Redelman, D. D., Blazar, B. R., Levy, R. B., & Murphy, W. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509249103 · Cited by 137
Transforming Growth Factor-β and Breast Cancer Risk in Women With Mammary Epithelial Hyperplasia
Gobbi, H., Dupont, W. D., Simpson, J. F., Plummer, W. D., Schuyler, P. A., Olson, S. J., Arteaga, C. L., & Page, D. L. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.24.2096 · Cited by 130
Self-citation
Transforming growth factor-β signaling: emerging stem cell target in metastatic breast cancer?
Tan, A. R., Alexe, G., & Reiß, M. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0184-1 · Cited by 128
Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells
Zhong, Z., Carroll, K. D., Policarpio, D., Osborn, C., Gregory, M., Bassi, R., Jimenez, X., Prewett, M., Liebisch, G., Persaud, K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1634 · Cited by 123
Reversal of Tumor-induced Immunosuppression by TGF-β Inhibitors
Wojtowicz‐Praga, S. (2003) · Investigational New Drugs · doi:10.1023/a:1022951824806 · Cited by 123

Authors: Arteaga, C. L., Hurd, S. D., Winnier, A. R., Johnson, M. D., Fendly, B. M., & Forbes, J. T.
Affiliations: Vanderbilt University (US)
ORCID: Arteaga, C L
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 1993-12-01
Volume: 92
Issue: 6
Pages: 2569-2576
ISSN: 0021-9738 (ISSN-L)
DOI: 10.1172/jci116871
PMC: PMC288452
OpenAlex: W2146839556
Cited by: 359
References: 40
Citations by year: 2026: 2 · 2025: 7 · 2024: 6 · 2023: 3 · 2022: 6 · 2021: 7 · 2020: 5 · 2019: 7 · 2018: 7 · 2017: 10 · 2016: 4 · 2015: 5 · 2014: 6 · 2013: 11 · 2012: 8
FWCI: 4.51
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: TGF-beta, anti-TGF-beta antibody, breast cancer, natural killer cells, tumor immunosuppression, tumor progression, metastasis, MDA-MB-231 cells, tumor microenvironment, host immune surveillance, tumor-host interaction
MeSH terms: Animals, Antibodies, Breast Neoplasms, Cell Division, Collagen, Cytotoxicity, Immunologic, Factor VIII, Female, Humans, Immunoglobulin G, Killer Cells, Natural, Lung Neoplasms, Mice, Nude, Neoplasm Metastasis, Neoplasm Transplantation, Neovascularization, Pathologic, Recombinant Proteins, Spleen, Transplantation, Heterologous, Tumor Cells, Cultured, Transforming Growth Factor beta, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks